The haemodynamic effects of a new beta-blocking agent, 'Sectral' (M & B I78o3A) 
Sectral, M & B 17803 (DL-I-(2-acetyl-4-butyramidophenoxy) -2 -hydroxy -3 -isopropylaminopropane hydrochloride), is a new cardioselective beta adrenergic antagonist. It blocks the myocardial beta, receptors by competitive inhibition and has in addition a membrane stabilizing and quinidine-like effect; it also has a weak inherent sympathomimetic action (May and Baker, Dagenham, England, I97I, personal communication) . There is a small effect on peripheral vascular dynamics, and the drug may produce a minor fall in arterial pressure and limb blood flow (C. F. George, R. A. Briant, F. Fenyvesi, and C. T. Dollery, 1971, personal communication) ; there is little or no effect on the bronchial beta2 receptors.
Preclinical studies have shown that the drug is well absorbed orally and has a plasma half-life of I 8 hours. The beta-blocking effect is more prolonged and the pharmacological half-life is I0 to I2 hours (May and Baker, 197I, personal communication (Mason, I969) . Force-velocity curves were constructed for each patient and for normal subjects according to the method of Mason, Spann, and Zelis (1970) (Bakst, Lewis, and Gotsman, I972) . The velocity of shortening of the contractile element was derived from the formula V00 = p/dt 32P which is based on the assumption that during isovolumic systole the velocity of the contractile element (V,6) is equal to the velocity of the series elastic element (V..).
The force-velocity curve constructed in this way has three components: an ascending limb (from zero velocity at LV end-diastolic pressure), a clearly defined point of inflexion, and a descending limb where velocity decreases as the pressure and load increases. The ascending limb of the curve depends on the preload, the inertia of the system, and the V,e; the point of inflexion represents the true peak velocity. The patients were then given io mg Sectral intravenously and the haemodynamic measurements repeated after I0 minutes. A further dose of 20 mg Sectral was then given (total dose of 30 mg beta-blocker) and io minutes later measurements were again made.
Finally, the patients were challenged with I0 [tg isoprenaline sulphate intravenously to see whether betablockade could be reversed. In 4 subjects, isoprenaline sulphate was also given before the beta-blocking drug so that the efficacy of beta-blockade could be assessed for the dosage used in this study.
Critique of methods
A fluid-filled catheter manometer system was used for pressure measurements: this provides reliable routine intravascular measurements but the frequency response of the system may distort the high frequency components of the pressure measurements and differentiation exaggerates the error (Yanof et al., I963; Gersh, Hahn, I97I) . The results are different if a catheter-tip micromanometer is used. For this reason peak V,. and Vmax were only measured in patients who had technically perfect pressure recordings. Moreover, while the velocity of contractile fibre shortening is readily measured in vitro, the validity of applying the technique to the intact man is under debate (Mason et al., I970; Sonnenblick, Parmley, and Urschel, I969; Pollack, I970; Noble, I972) . Finally, we clearly recognize that the series elastic element may be different in normal subjects and in patients with cardiac diseaseparticularly left ventricular aneurysm -and the constant 32, which is used in the calculation of Vmax, may not always be correct (Sonnenblick, I964; Parmley and Sonnenblick, I967, I97I) . measured from the electrocardiogram, phonocardiogram, and a simultaneous pressure recording in the ascending aorta. The delay time of the catheter manometer system was determined from a comparison of the dicrotic notch of the aortic pressure tracing with the aortic component of the second heart sound and the appropriate correction made in the measurements. The systolic time intervals have two components: pre-ejection phase (PEP), from the earliest q wave of the electrocardiogram to the instant of aortic pressure rise, and left ventricular ejection time (LVET) from aortic valve opening to its closure. The PEP/LVET ratio was also calculated -this ratio correlates with LV ejection fraction (Garrard, Weissler, and Dodge, 1970) .
Routine cardiac catheterization was followed by left ventricular cineangiography in the right anterior oblique view using 50 ml of 76 per cent Urografin. Selective coronary angiography was performed in several oblique views in I2 patients (Judkins, I967) . The patients were allowed to rest after the angiographic manipulations.
Control measurements were made at least i5 minutes after angiography: they were cardiac index, stroke index, heart rate, left ventricular and arterial pressures,
Results
The haemodynamic measurements before and after the pharmacological interventions are shown in Table 2 and the percentage changes are shown in Table 3 .
Heart rate Sectral decreased heart rate in all three groups of patients: after io mg of the drug heart rate fell by 4 per cent in patients with coronary artery disease, i5 per cent in patients with aneurysm, and I4 per cent in the control subjects. After the larger dose, the mean percentage change in each group was smaller, i.e. -2 per cent in Group i, -8 per cent in Group 2, and -i i per cent in the control subjects (Fig. i) .
The beta-blocking effect could be overcome in all patients by I0 jg isoprenaline sulphate but the tachycardia produced was mild: it was less than the comparative tachycardia induced before administra- The range of value is given in brackets. Same abbreviations as Table 2. tion of the beta-blocking drug. This indicates that effective beta-blockade had been produced.
Stroke index
Stroke index fell slightly in all three groups of patients (Fig. 2) . The change was related to dose. The greatest change was seen in the patients with LV aneurysm after administration of 30 mg Sectral (-IO%).
Cardiac index
The cardiac index fell by IO to 2I per cent in the 3 groups (Fig. 3) . (Fig. 4) . Peak,, and Vmax were also diminished: peak Vc8 fell by 14 per cent in Group I, I3 per cent in Group 2, and 4 per cent in Group 3, while Vmax fell by I7 per cent in Group I, I5 per cent in Group 2, and I4 per cent in the control subjects (Fig. 5) .
Myocardial contractility was improved by the isoprenaline challenge; there were insufficient measurements to make a meaningful comparison of the response to isoprenaline before and after Sectral.
LV end-diastolic pressure The change in end-diastolic pressure varied. Though the overall mean pressure increased, LV end-diastolic pressure fell in half the patients in Group i and Group 3; it always increased in patients with regional asynergy and left ventricular fibrosis.
Mean arterial pressure
There was little change in mean arterial pressure after the beta-blocker: there was a small decrease in arterial pressure in Groups i and 3, and there was a small increase in patients with left ventricular aneurysm after the smaller dose of the drug (Fig. 6 ).
Systolic time intervals
Pre-ejection phase (PEP) was slightly prolonged in all three groups of patients after administration of Sectral, a consequence of the reduced contractility and decreased LVdp/dt. LVET was essentially unchanged in this study. The PEP/LVET ratio varied, and 9% in Group 3). This indicates that there was a small decrease in LV ejection fraction after administration of Sectral (Garrard et al., 1970) . Discussion Beta adrenergic blocking agents Beta adrenergic blocking agents are now widely used in the management of angina pectoris, arrhythmias, hypertension, thyrotoxicosis, and anxiety states. Propranolol is the prototype beta antagonist but it produces widespread beta-blockade: it blocks bronchial beta2 receptors and is therefore of limited value in patients with pulmonary disease. It also has a membrane stabilizing and cardiac depressant action ('quinidine-like' effect) . This effect may be desirable in the management of certain arrhythmias but it further reduces cardiac and stroke output (Brunner, Hedwall, and Meier, I97I) .
The newer beta adrenergic antagonists aim at cardioselectivity, so that, in ideal circumstances, bronchial and arteriolar beta2 receptors are undisturbed. Fortunately several of these drugs have intrinsic sympathomimetic activity so that the net effect on cardiac output is negligible. 
Published reports
The actions and uses of the different blocking agents have been studied in great detail and formed the subject of many reports. Difficulties have been introduced as different methods are used to assess the efficacy of beta-blockade. The dose of the drugs used and the routes of administration have varied in each trial. There is also an inter-and intra-species difference. Many patients who have been studied were also receiving digitalis: digitalis alters myocardial contractility. Moreover, the study of patients with different pathological conditions collectively known as 'cardiac disease' has made a comparative evaluation difficult: some patients had valvular dysfunction, others had abnormal myocardial contractility with or without regional asynergy, while the effect of a beta-blocking agent on ventricular function is difficult to assess in patients who also have atrial fibrillation, since atrioventricular conduction and the rate of ventricular response are also altered by the beta-blocker.
Present study
We selected for study control subjects and two groups of patients in whom beta adrenergic blockade is commonly used for the relief of angina and the control of arrhythmias. The isoprenaline response in 4 patients before and after administration of the drug indicates that effective beta-blockade was produced. There was a negative chronotropic effect both after I0 mg and after 30 mg Sectral. Left ventricular contractility was altered and there was a fall in LVdp/dt, peak Vce, and Vmax. The mean arterial pressure was slightly reduced and LV end-diastolic pressure slightly raised: in patients with left ventricular asynergy, the arterial pressure rose marginally and the LV end-diastolic pressure was significantly increased, a consequence of the regional fibrosis of the ventricle. The net effect of these changes was a small decrease in stroke index in all three groups of patients and a fall in cardiac index which was small in the patients with cardiac disease but slightly greater in the normal subjects who had a higher resting cardiac index. The changes in contractility and cardiac output produced by Sectral are less obvious than those produced by propranolol, but greater than those of practolol (May and Baker, 1971, personal communication; Finegan et al.,I972 Gibson and Coltart, I972) .
